NICE’s discounting review: clear thinking on rational revision meets obstacle of industrial interests

PharmacoEconomics

7 February 2021 - NICE recently published a review of discounting practice and theory as part of a consultation on its current methods guidelines. 

The review examines the case for revision or retention of current methods. 

The changes considered include eliminating favourable rates in certain special cases and the reduction of the base case rate for costs and health effects from 3.5 to 1.5%.

Read PharmacoEconomics Current Opinion

Michael Wonder

Posted by:

Michael Wonder